Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases

Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases

Background: Recombinant human hyaluronidase (rHuPH20)-facilitated subcutaneous infusion of immunoglobulin (fSCIG; HyQvia) is a new Ig treatment combining the advantages of intravenously and conventional subcutaneously-administered immunoglobulin (Ig) with infusion at rates, volumes and frequencies s...

Full description

Bibliographic Details
Main Authors: Lina Laguado, Richard L. Wasserman, Isaac Melamed, Lisa Kobrynski, Sudhir Gupta, Werner Engl, Heinz Leibl, Leman Yel
Format: Article
Language:Spanish
Published: Colegio Mexicano de Inmunología Clínica y Alergia, A.C. 2018-06-01
Series:Revista Alergia México
Subjects:
recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin
primary immunodeficiency diseases
Online Access:http://revistaalergia.mx/ojs/index.php/ram/article/view/496

Similar Items

Similar Items